Foundation Medicine's New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration | Business Wire
Comprehensive genomic profiling in oncology – from vision to reality | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Multi-gene Testing (NGS) for PIK3CA Mutations
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin | PLOS ONE
Foundation Medicine wins FDA OK for pan-cancer liquid biopsy test
With its liquid biopsy approval, Foundation Medicine takes on Guardant | Evaluate
AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval | Evaluate
Foundation Medicine Liquid Biopsy Gets FDA Okay – ISPE Boston
FoundationOne Liquid CDx
FoundationOne Liquid CDx
Foundation Medicine | A World-leading Molecular Insights Company
Foundation Medicine touts concordance ahead of FDA ruling on liquid biopsy test - MedCity News
FoundationOne / Molekulares-Tumorprofiling – USZ
Foundation Medicine to launch liquid biopsy companion diagnostic following FDA approval - MedCity News
FoundationOne Liquid CDx
FoundationOne Liquid CDx | Foundation Medicine
Latest Medical News
Foundation Medicine Inks $111.5M Genomic Profiling Contract with VA
FoundationOne Liquid CDx
Roche France, Foundation Medicine and the Institute Gustave Roussy announce unique partnership to provide in-house liquid biopsy genomic testing to cancer patients in France | Gustave Roussy
FoundationOne Liquid
Foundation Medicine receives FDA approval for pan-tumour biopsy test
FoundationOne Liquid CDx
Sep 09, 2021| Information meeting on FoundationOne CDx Cancer Genomic Profile
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer | Nature Communications
FoundationOne Liquid CDx (F1 Liquid CDx) – P190032/S005 | FDA
